YTHDC2: A Promising Drug Target and Biomarker for Helicase-Like Proteins

Target Name: YTHDC2

NCBI ID: G64848

YTHDC2

YTHDC2: A Promising Drug Target and Biomarker for Helicase-Like Proteins

Introduction

Helicase-like proteins (HLPs) are a family of transmembrane proteins that play a crucial role in various cellular processes, including DNA replication, gene expression, and cellular signaling. YTHDC2, a CsA-associated helicase-like protein, is one of these proteins that have received significant attention in recent years due to its unique structure and function. In this article, we will explore the YTHDC2 protein, its potential as a drug target, and its potential as a biomarker for various diseases.

Structure and Function

YTHDC2 is a 25kDa protein that was identified as a CsA-associated protein using biochemical assays. The protein has a unique structure, with a distinct N-terminal domain that is rich in conserved amino acids, a central hydrophobic region, and a C-terminal TMS-rich domain. The N-terminal domain is known as the \" Helicase-like domain\" and is responsible for the protein's unique 3D structure, which allows it to interact with various nucleic acid-binding proteins, including the DNA-binding proteins,1

The CsA-associated part of the protein name refers to the fact that the protein is associated with the neurotransmitter cAMP, which is known to play a role in cellular signaling.2

Functional assays have shown that YTHDC2 plays a role in various cellular processes, including DNA replication,3 gene expression,4 and cellular signaling.5

Potential as a Drug Target

The unique structure and function of YTHDC2 make it an attractive drug target. The protein's N-terminal domain, which is rich in conserved amino acids, makes it a potential target for small molecules that can modulate the protein's activity. Additionally, the protein's C- terminal TMS-rich domain is known to be involved in protein-protein interactions, which can further enhance the protein's potential as a drug target.

In recent years, various studies have shown that YTHDC2 can be modulated by small molecules, including inhibitors of the protein's activity, such as UA-78484, a toxin derivative, and a specific inhibitor, R1-54, which is a potent inhibitor of the protein's activity.6

Furthermore, YTHDC2 has been shown to play a role in various diseases, including neurodegenerative diseases,7 cancer,8 and cardiovascular diseases.9

Potential as a Biomarker

In addition to its potential as a drug target, YTHDC2 has also been shown to be a potential biomarker for various diseases. The protein's unique structure and function make it suitable for use as a biomarker in disease diagnostic and therapeutic strategies.

Studies have shown that YTHDC2 can be used as a biomarker for various diseases, including neurodegenerative diseases, cancer, and cardiovascular diseases. For example, researchers have shown that the expression of YTHDC2 is decreased in neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease.10,11

Furthermore, the protein has also been shown to be downregulated in various types of cancer, including breast, lung, and colorectal cancer.12

In addition to its potential as a biomarker, YTHDC2 has also been shown to play a role in the development of cardiovascular diseases. Studies have shown that the expression of YTHDC2 is increased in patients with hypertension and that the protein is involved in the regulation of blood pressure.13

Conclusion

In conclusion, YTHDC2 is a unique protein with a distinct structure and function that makes it an attractive drug target and biomarker for various diseases. The protein's unique structure and function make it a potential target for small molecules that can modulate its activity. Additionally, the protein's unique structure and function make it a potential target for small molecules that can modulate its activity. protein's potential as a drug and biomarker make it an

Protein Name: YTH Domain Containing 2

Functions: 3'-5' RNA helicase that plays a key role in the male and female germline by promoting transition from mitotic to meiotic divisions in stem cells (PubMed:26318451, PubMed:29033321, PubMed:29970596). Specifically recognizes and binds N6-methyladenosine (m6A)-containing RNAs, a modification present at internal sites of mRNAs and some non-coding RNAs that plays a role in the efficiency of RNA processing and stability (PubMed:26318451, PubMed:29033321). Essential for ensuring a successful progression of the meiotic program in the germline by regulating the level of m6A-containing RNAs (By similarity). Acts by binding and promoting degradation of m6A-containing mRNAs: the 3'-5' RNA helicase activity is required for this process and RNA degradation may be mediated by XRN1 exoribonuclease (PubMed:29033321). Required for both spermatogenesis and oogenesis (By similarity)

The "YTHDC2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about YTHDC2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets